Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 2007

A Simplified Premedication Protocol for One-Hour Paclitaxel Infusion in Various Combinations

Christos Kosmas, Nicolas Tsavaris

Med Sci Monit 2006; 12(11): CR462-466 :: ID: 462697

Abstract

Background: Many investigations have focused on optimal doses/schedules since regulatory agency approval of paclitaxel (Taxol). Paclitaxel is generally administered at doses of 175–225 mg/m[sup]2[/sup] over 3 hours or 135–175 mg/m[sup]2[/sup] over 24 hours, every 3 weeks. The purpose of this study was to simplify administration
and render it suitable and practical in the outpatient setting. Using this rationale, the duration
of administration was decreased to one hour, with a minimized premedication regimen.
Material/Methods: One hundred patients who were to receive paclitaxel-based chemotherapy combinations entered the study. Tumor types were non-small-cell lung cancer (NSCLC, n=40), small-cell lung cancer (SCLC, n=18), breast cancer (n=12), head and neck cancer (n=16), and ovarian cancer (n=14). Sixty patients received paclitaxel at 175 mg/m[sup]2[/sup] and the remaining 40 at 225 mg/m[sup]2[/sup]. The premedication regimen consisted of a single dose of dexamethasone 20 mg, dimethindene maleate (Fenistil)
4 mg, and ranitidine (Zantac) 50 mg, followed by the standard antiemetic therapy. Paclitaxel was
always administered before other chemotherapeutic agents, i.e. ifosfamide and/or platinum compounds,
except for breast cancer, where epirubicin preceded paclitaxel administration.
Results: Hypersensitivity reactions were recorded in 7 patients (7.0%) and were not infl uenced by age, gender, disease, dose schedule, or cycles of therapy. No serious adverse events were observed.
Conclusions: The simplifi ed administration dose schedule for paclitaxel is safe and accommodates its combination with other cytostatic agents.

Keywords: Antineoplastic Agents, Phytogenic - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Dexamethasone - administration & dosage, Dimethindene - administration & dosage, Neoplasms - drug therapy, Paclitaxel - administration & dosage, Premedication, Ranitidine - administration & dosage, Time Factors

Add Comment 0 Comments

Editorial

01 June 2024 : Editorial  

Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals

Dinah V. Parums

DOI: 10.12659/MSM.945315

Med Sci Monit 2024; 30:e945315

0:00

In Press

Clinical Research  

Hemorrhagic Cysts in the Pancreas: Risk Factors, Treatment, and Outcomes – Insights from a Single-Center Study

Med Sci Monit In Press; DOI: 10.12659/MSM.941955  

0:00

Clinical Research  

Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Managem...

Med Sci Monit In Press; DOI: 10.12659/MSM.944063  

0:00

Database Analysis  

Comprehensive Analysis of Sphingolipid Metabolism-Related Genes in Osteoarthritic Diagnosis and Synovial Im...

Med Sci Monit In Press; DOI: 10.12659/MSM.943369  

0:00

Review article  

Applications of Functional Near-Infrared Spectroscopy (fNIRS) Neuroimaging During Rehabilitation Following ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943785  

0:00

Most Viewed Current Articles

14 Dec 2022 : Clinical Research   1,441,389

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

17 Jan 2024 : Review article   1,376,349

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   690,122

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial   50,127

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750